FMP

FMP

Enter

ImmunityBio, Inc. (NASDAQ:IBRX) Financial Overview

- (Last modified: Nov 19, 2024 9:03 AM)

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • ImmunityBio's Return on Invested Capital (ROIC) is an impressive 319.64%, significantly higher than its peers.
  • The company's Weighted Average Cost of Capital (WACC) stands at 8.13%, leading to a ROIC to WACC ratio of 39.30.
  • Compared to its peers, ImmunityBio is generating returns well above its cost of capital, indicating efficient capital use and value creation for investors.

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company focused on developing innovative therapies to treat cancer and infectious diseases. The company aims to harness the power of the immune system to combat these diseases. In the competitive landscape, ImmunityBio stands out due to its impressive financial metrics, particularly its Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC).

ImmunityBio's ROIC is an impressive 319.64%, while its WACC is 8.13%. This results in a ROIC to WACC ratio of 39.30, indicating that the company is generating returns significantly above its cost of capital. This high ratio suggests that ImmunityBio is using its capital efficiently, creating value for its investors.

In contrast, ImmunityBio's peers, such as BridgeBio Pharma, Inc. (BBIO) and Sana Biotechnology, Inc. (SANA), show negative ROIC figures of -114.85% and -105.16%, respectively. Their ROIC to WACC ratios are -14.58 and -10.70, indicating that these companies are not currently generating returns above their cost of capital. This is a common scenario for clinical-stage biotechnology companies, which often face high research and development expenses.

Other peers like Nkarta, Inc. (NKTX) and Allogene Therapeutics, Inc. (ALLO) also report negative ROICs of -31.74% and -61.02%, respectively. Their ROIC to WACC ratios are -4.87 and -8.29, further highlighting the challenges these companies face in generating returns above their cost of capital. Despite these challenges, ImmunityBio's strong financial performance sets it apart in the biotechnology sector.

Recursion Pharmaceuticals, Inc. (RXRX) also struggles with a negative ROIC of -72.55% and a ROIC to WACC ratio of -9.14. This further emphasizes ImmunityBio's superior ability to generate returns on its invested capital relative to its cost. ImmunityBio's strong capital efficiency positions it as a potentially attractive investment within its peer group, assuming other factors such as market conditions and company-specific risks are favorable.

Other Blogs

May 14, 2024 11:41 AM - Sanzhi Kobzhan

The easiest way to calculate stock’s target price and why the target price is important.

A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...

blog post title

May 24, 2024 9:30 AM - Rajnish Katharotiya

How to Access and Analyze Earnings Call Transcripts

Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...

blog post title

May 27, 2024 3:30 PM - Rajnish Katharotiya

The best 5 GPU stocks other than NVDA

In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep